HLB BioStep Co

HLB BioStep Co Liabilities

The The Liabilities of HLB BioStep Co (278650.KQ) as of Oct 30, 2026 is 54.64 B KRW. In the previous year, The Liabilities was 56.45 B KRW — a change of -3.22% (lower).

Liabilities

54.64 BKRW

YoY

-3.22%

Last updated:

In 2025, HLB BioStep Co's total liabilities amounted to 54.64 B KRW, a -3.22% difference from the 56.45 B KRW total liabilities in the previous year.

The HLB BioStep Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
23.07 B KRW
Jan 1, 2019
19.67 B KRW
Jan 1, 2020
20.57 B KRW
Jan 1, 2021
30.04 B KRW
Jan 1, 2022
101.91 B KRW
Jan 1, 2023
68.14 B KRW
Jan 1, 2024
56.45 B KRW
Jan 1, 2025
54.64 B KRW
The HLB BioStep Co Liabilities history
YEARLiabilitiesYoY
54.64 BKRW-3.22%
56.45 BKRW-17.15%
68.14 BKRW-33.14%
101.91 BKRW+239.26%
30.04 BKRW+46.02%
20.57 BKRW+4.60%
19.67 BKRW-14.76%
23.07 BKRW+38.33%
16.68 BKRW+49.28%
11.17 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing HLB BioStep Co's Liabilities

HLB BioStep Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating HLB BioStep Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing HLB BioStep Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

HLB BioStep Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in HLB BioStep Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about HLB BioStep Co stock

The Liabilities of HLB BioStep Co is 54.64 B KRW in 2025.

The Liabilities of HLB BioStep Co changed from 56.45 B KRW to 54.64 B KRW, representing a -3.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's HLB BioStep Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HLB BioStep Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HLB BioStep Co